Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

Table 3 Efficacy outcomes with lenalidomide in patients with MCL after ibrutinib failure or intolerance

Outcome	L (n = 13)		L + R (n = 11)		L + other^a (n = 34)		Overall (N = 58)
Outcome	No.	%	No.	%	No.	%	No.	%
Best response by investigator’s assessment
ORR	2	15	3	27	12	35	17	29
95% CI	2–45%		6–61%		20–54%		18–43%
CR	0	0	1	9	7	21	8	14
PR	2	15	2	18	5	15	9	15
SD	0	0	1	9	3	9	4	7
Relapse/PD	8	62	3	27	16	47	27	47
Unknown	3	23	2	18	3	9	8	14
Missing	0	0	2	18	0	0	2	3
Duration of response, weeks
KM median	3		20		NA		20
95% CI	NA to NA		NA to NA		16.4 to NA		2.9 to NA

CI confidence interval, CR complete response, KM Kaplan-Meier, L lenalidomide, L + R lenalidomide plus rituximab, MCL mantle cell lymphoma, NA not applicable, PD progressive disease, PR partial response, SD stable disease
^aAdditional file 1: Table S2 lists the other treatments

ISSN: 1756-8722